ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

AUTL vs CCCC // NET PROFIT MARGIN

Autolus Therapeutics plc (NASDAQ) VS. C4 Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: AUTL 2 — CCCC 1
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (AUTL VS. CCCC) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC AUTL CCCC SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin -27.80% — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield — -24.46% — TIE /fcf-yield <GO>
Operating Margin -60.00% -60.00% 0.00 TIE /operating-margins <GO>
Net Profit Margin ACTIVE -60.00% -60.00% 0.00 TIE /net-margins <GO>
Revenue Growth (YoY) 180.00% 1.00% +179.00 AUTL /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 0.20 0.20 0.00 TIE /balance-sheet <GO>
Piotroski F-Score Quality 3/9 3/9 0.00 TIE /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 36.6 57.0 -20.46 CCCC /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $420.5M $406.0M $14.6M AUTL /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR AUTL REV CCCC REV AUTL GROSS % CCCC GROSS % AUTL FCF CCCC FCF
FY 2025 $75.4M $35.9M -27.8% — -$302.6M -$99.3M
FY 2024 $10.1M $35.6M -12.5% — -$228.3M -$65.3M
FY 2023 $1.7M $20.8M — — -$145.6M -$106.8M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
AUTL // BETA —
CCCC // BETA —